恒基达鑫(002492) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥84,141,740.74, a decrease of 10.00% compared to ¥93,486,494.07 in the same period last year[7] - Net profit attributable to shareholders was ¥20,796,008.85, down 15.21% from ¥24,525,475.36 year-on-year[7] - Basic and diluted earnings per share were both ¥0.0513, reflecting a decline of 15.35% from ¥0.0606[7] - Operating profit fell to ¥25,478,934.88, down from ¥29,150,378.50, representing a decrease of about 12.5%[21] - Net profit decreased to ¥21,006,064.47 from ¥24,345,406.10, reflecting a decline of approximately 13.5%[21] - Total operating revenue decreased to ¥84,141,740.74 from ¥93,486,494.07, a decline of approximately 9.5% year-over-year[19] - Cash flow from operating activities generated ¥81,920,427.48, down from ¥210,658,737.26, a significant decrease of approximately 61%[22] - Research and development expenses decreased to ¥2,115,258.37 from ¥3,603,346.74, a reduction of approximately 41.3%[19] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 61.11%, amounting to ¥81,920,427.48 compared to ¥210,658,737.26 in the previous year[7] - The company reported a significant increase in cash and cash equivalents, rising by 53.42% to ¥336,315,547.56 due to increased bill financing[12] - Cash inflow from investment activities increased to ¥326,896,245.33 from ¥205,412,055.72, an increase of about 59%[22] - Cash inflow from borrowings amounted to $160.94 million, an increase from $101.36 million in the previous period, reflecting a growth of 58.5%[23] - The net increase in cash and cash equivalents was $117.02 million, down from $173.37 million year-over-year[23] - The ending balance of cash and cash equivalents stood at $335.62 million, compared to $383.01 million in the previous period, a decrease of 12.4%[23] Assets and Liabilities - Total assets increased by 4.64% to ¥2,196,392,789.19 from ¥2,099,053,070.92 at the end of the previous year[7] - The company's total current assets increased to ¥1,033,730,536.55 from ¥940,234,083.27, reflecting a growth of approximately 9.5%[16] - Total liabilities increased to ¥475,952,994.40 from ¥399,749,949.38, indicating a rise of about 19.0%[17] - Non-current liabilities rose to ¥223,963,828.10 from ¥198,026,768.22, reflecting an increase of about 13.1%[17] - The company recorded a decrease in short-term borrowings from ¥80,194,603.89 to ¥49,351,577.09, a reduction of approximately 38.4%[17] Shareholder Information - The company’s total equity attributable to shareholders increased by 1.24% to ¥1,703,951,771.20 from ¥1,683,078,923.24[7] - The total number of common shareholders at the end of the reporting period is 18,393[13] - The largest shareholder, Zhuhai Shiyou Chemical Co., Ltd., holds 41.58% of shares, totaling 168,414,300 shares, with 10,790,000 shares pledged[13] Other Income and Gains - The company experienced a 6939.22% increase in fair value gains, reaching ¥3,681,856.80, primarily from financial products[12] - The company recorded a 410.14% increase in non-operating income, totaling ¥181,988.73, due to insurance compensation received[12] - The company reported a significant increase in other income to ¥1,207,646.94 from ¥704,679.57, an increase of approximately 71.4%[19]